胰腺癌患者接种多种MHC I/II类限制性WT1肽脉冲树突状细胞加化疗后的预后标志物。

Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.

作者信息

Takakura Kazuki, Koido Shigeo, Kan Shin, Yoshida Kosaku, Mori Masako, Hirano Yuta, Ito Zensho, Kobayashi Hiroko, Takami Shinichiro, Matsumoto Yoshihiro, Kajihara Mikio, Misawa Takeyuki, Okamoto Masato, Sugiyama Haruo, Homma Sadamu, Ohkusa Toshifumi, Tajiri Hisao

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo, Japan Department of Oncology, The Jikei University School of Medicine, Tokyo, Japan

出版信息

Anticancer Res. 2015 Jan;35(1):555-62.

PMID:25550602

Abstract

BACKGROUND/AIM: Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients.

MATERIALS AND METHODS

Laboratory data from seven patients with pancreatic cancer who underwent combined DC/WT1-I/II vaccination and chemotherapy were analyzed. The DC phenotypes and plasma cytokine profiles were analyzed via flow cytometry.

RESULTS

The post-treatment neutrophil to lymphocyte (N/L) ratio was a treatment-related prognostic factor for better survival. Moreover, the mean fluorescence intensities (MFIs) of human leukocyte antigen (HLA)-DR and cluster of differentiation (CD)83 on DCs were significantly increased after chemoimmunotherapy. Interestingly, interleukin (IL)-6 level in plasma was significantly increased after chemoimmunotherapy in non-super-responders.

CONCLUSION

An increased N/L ratio, as well as HLA-DR and CD83 MFI levels may be prognostic markers of longer survival in patients with advanced pancreatic cancer who undergo chemoimmunotherapy.

摘要

背景/目的：用三种主要组织相容性复合体（MHC）I类和II类（DC/WT1-I/II）限制性肾母细胞瘤1（WT1）肽脉冲处理的树突状细胞（DC）与化疗联合治疗，可能会使胰腺癌患者的病情稳定。